Copyright: Hanson Wade 2025

This planner has been created through considerable effort by Hanson Wade’s
Beacon ADC research team. The terms of subscription restrict usage of this work to
those who are named subscribers to the service. Unauthorized copying and/or
distribution of this document constitutes copyright infringement. If you are in doubt
about whether you are entitled to receive a copy of this planner, check with your
account holder or with Hanson Wade ([email protected])
• The American Association for Cancer Research (AACR) Annual Meeting 2025 will be held at the McCormick Place Convention
Center in Chicago, IL from the 25th - 30th April 2025. A full list of abstracts for the conference can be found here.

• Our analyst team has screened the abstracts due to be presented and identified 311 abstracts (35 clinical, 263 preclinical, and 13
embargoed) associated with drug or trial records on Beacon ADC.​

• This Pre-Conference Planner lists abstracts in order of presentation categorized by clinical trial and preclinical drug data with links to
each abstract, and the associated record on Beacon.

• We hope you find this Pre-Conference Planner useful and are as excited as us to see the latest developments in the ADC field.
 Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor Target
and Location​
SHR-A1811, a HER2-directed antibody-drug
conjugate (ADC), in advanced HER2 -
Jiangsu Hengrui Pharmaceutical April 27, 2025, 03:15 PM -
CT009 mutant non-small cell lung cancer (NSCLC): NCT04818333 HER-2
Co., Ltd. 3:25 PM
Updated phase 2 results from HORIZON-
Lung
Phase I dose-escalation and expansion
study of JS107, a claudin 18.2 (CLDN18.2)-
April 27, 2025, 03:30 PM -
CT010 targeting antibody-drug conjugate (ADC), as NCT05502393 Shanghai Junshi Bioscience Co., Ltd CLDN18.2
3:40 PM
monotherapy or in combination for patients
(pts) with advanced solid tumors
 Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor Target
and Location​
Preliminary activity and safety of OBT076 in
patients with CD205 positive solid tumors: April 28, 2025, 09:00 AM -
CT044 / 23 NCT04064359 Oxford BioTherapeutics CD205
Results from the phase 1b part B expansion 12:00 PM; Section 49
cohort

A phase 1/2 trial of TAC-001 (TLR9 agonist-

April 28, 2025, 09:00 AM -
CT045 / 24 CD22 mAb) in advanced or metastatic solid NCT05399654 Tallac Therapeutics Inc TLR9
12:00 PM; Section 49
tumors

Seagen Inc/GenMab A/S,

Molecular profiling of tisotumab vedotin- Gynecologic Oncology Group,
treated patients identified immune pathways Belgian Gynaelogical Onology April 28, 2025, 02:00 PM -
3093 / 1 NCT03438396 Tissue Factor
associated with clinical activity, supporting Group, Belgium, European Network 5:00 PM; Section 23
the multimodal mechanism of action of Gynaecological Oncological Trial
Groups (ENGOT)
 Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor Target
and Location​
A phase 1a/b, open-label, dose-escalation
study of 225 Ac-ABD147 for locally
advanced or metastatic small cell lung April 28, 2025, 02:00 PM -
CT107 / 2 NCT06736418 Abdera Therapeutics Inc. DLL3
cancer and large cell neuroendocrine 5:00 PM; Section 51
carcinoma of the lung following platinum-
based chemotherapy

Phase I open-label, multi-center study to

evaluate the safety, tolerability, dosimetry,
April 28, 2025, 02:00 PM -
CT112 / 7 and preliminary activity of FXX489 ([ 177 NCT06562192 Novartis Pharmaceuticals AG Undisclosed
5:00 PM; Section 51
Lu]Lu-NNS309) in patients with pancreatic,
lung, breast and colorectal cancers
 Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor Target
and Location​

Zilovertamab vedotin in pediatric and young

Merck Sharp & Dohme Ltd/ Daiichi April 28, 2025, 02:00 PM -
CT119 / 14 adult hematologic malignancies or solid NCT06395103 ROR1
Sankyo, Inc. 5:00 PM; Section 51
tumors: Phase 1/2 LIGHTBEAM-U01A study

A phase 1/2a, multicenter, open-label, first in

human study of a bispecific ADC targeting April 28, 2025, 02:00 PM -
CT121 / 16 NCT06554795 DualityBio Inc. B7-H3
B7H3 and PDL1 (DB-1419) in advanced or 5:00 PM; Section 51
metastatic solid tumors

ALK201, a first-in-class FGFR2b-targeting

antibody-drug conjugate for patients with Shanghai Allink Biotherapeutics Co., April 28, 2025, 02:00 PM -
LB227 / 1 NCT06656390 FGFR2b
FGFR2b+ gastric cancer and other solid Ltd 5:00 PM; Section 54
tumors
 Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor Target
and Location​

BEHOLD-1: A Phase 1 Dose Escalation

Study of GSK5733584, a B7-H4-Targeted
Antibody-Drug Conjugate, in Patients With April 29, 2025, 09:00 AM -
CT188 / 5 NCT06431594 GlaxoSmithKline B7-H4
Advanced Solid Tumors, Including Dose 12:00 PM; Section 50
Expansion in Patients With Endometrial and
Platinum-Resistant Ovarian Cancer

Phase 1 dose escalation and expansion

study of the PTK7-targeted antibody-drug April 29, 2025, 09:00 AM -
CT196 / 13 NCT06752681 Day One Biopharmaceuticals Inc PTK7
conjugate DAY301 in patients with locally 12:00 PM; Section 50
advanced or metastatic solid tumors
 Therapeutic Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor
class ​ and Location​
Multiple Myeloma Research
The immunomodulatory effects of
Consortium/ AbbVie Ltd, Genentech,
daratumumab-based therapy on functional
Inc. , Takeda, Eli Lilly and Company, April 29, 2025, 02:00 PM -
5258 / 18 high-risk relapse/refractory multiple myeloma NCT03732703 BCMA
Janssen, LP, GlaxoSmithKline, 5:00 PM; Section 6
(fHRMM) patients enrolled in the MyDRUG
Karyopharm Therapeutics, Inc,
trial
Celgene

Baseline serum protein analysis of patients NCT03734029

with interstitial lung disease/pneumonitis
Daiichi Sankyo, Inc/ AstraZeneca April 29, 2025, 02:00 PM -
5928 / 20 (ILD) in 3 trastuzumab deruxtecan (T-DXd) NCT03505710 HER 2
PLC 5:00 PM; Section 32
trials: DESTINY-Breast01, DESTINY-
Breast04, and DESTINY-Lung01
NCT03248492

A phase 2 study of BPM31510 (a lipid

nanodispersion of oxidized CoQ10) with
vitamin K in combination with standard of April 29, 2025, 02:00 PM -
CT242 / 11 NCT01251562 Berg, LLC Undisclosed
care (SOC) RT and TMZ in glioblastoma 5:00 PM, Section 51
multiforme (GBM) patients without prior
therapy
 Therapeutic Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor
class ​ and Location​
An open-label, multicenter, phase 2 study of
trastuzumab deruxtecan (T-DXd) in patients April 29, 2025, 02:00 PM -
CT249 / 18 NCT04482309 AstraZeneca PLC HER-2
(pts) with HER2-expressing solid tumors: 5:00 PM, Section 51
DESTINY-PanTumor02 (DP-02) Part 2

Trofuse-023: A phase 3, randomized, open-

label study of pembrolizumab with or without
maintenance sacituzumab tirumotecan (sac- April 29, 2025, 02:00 PM -
CT250 / 19 NCT06422143 Merck & Co Inc TROP-2
TMT) as first-line treatment for metastatic 5:00 PM, Section 51
squamous non-small-cell lung cancer
(NSCLC)
 Therapeutic Date, Time
Abstract ID​ Title​ Trial ID​ Sponsor
class ​ and Location​

Exploratory biomarker analysis of

trastuzumab deruxtecan (T-DXd) treatment
Daiichi Sankyo, Inc/ Daiichi Sankyo, April 30, 2025, 09:00 AM -
7148 / 12 for HER2-positive (HER2+) metastatic NCT04744831 HER-2
Inc. 12:00 PM, Section 32
colorectal cancer (mCRC) in DESTINY-
CRC02 (DC-02)

Trop-2 expression and association with

efficacy in patients treated with sacituzumab
Gilead Sciences/ Merck Sharp & April 30, 2025, 09:00 AM -
LB399 / 5 govitecan + pembrolizumab +/- carboplatin NCT05186974 TROP-2
Dohme Corp. 12:00 PM, Section 49
in the EVOKE-02 study of non-small cell
lung cancer
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Identification of novel senolytic targets and

development of conditionally active biologic- April 27, 2025, 02:00 PM - 5:00 PM,
296 / 5 CAB-ADC BioAtla Inc Undisclosed
based-drug conjugates for targeted senescence- Section 13
associated secretory phenotype elimination in vivo

Long-term tumor growth inhibition and extended

survival with TD001, a novel optimized PSMA- Institute of Oncology April 27, 2025, 02:00 PM - 5:00 PM,
311 / 3 TD001 PSMA
targeting ADC, in PSMA-expressing CRPC CDX Research Bellinzona Section 15
castrated mouse models

Improved tumor penetration and cytotoxic payload

release with TD001, a novel PSMA-targeting ADC
Institute of Oncology April 27, 2025, 02:00 PM - 5:00 PM,
314 / 6 with optimized linker-payload composition, in TD001 PSMA
Research Bellinzona Section 15
PSMA-expressing CRPC CDX castrated mouse
models
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Optimal free exatecan payload tumor/plasma ratio

Institute of Oncology April 27, 2025, 02:00 PM - 5:00 PM,
318 / 10 of TD001, a new ADC against PSMA, in CRPC TD001 PSMA
Research Bellinzona Section 15
CDX mouse models

Nonclinical characterization of the secondary

mechanisms of action of PF-08046054 (PDL1V),
April 27, 2025, 02:00 PM - 5:00 PM,
322 / 14 a novel vedotin ADC directed to PD-L1 that SGN-PDL1V Pfizer Inc; Seagen Inc. PD-L1
Section 15
selectively depletes tumor cells without depleting
healthy immune cells

Preclinical evaluation of SDV2102, a novel PSMA- April 27, 2025, 02:00 PM - 5:00 PM,
323 / 15 SDV2102 Syndivia SAS PSMA
targeting DAR1 ADC for mCRPC treatment Section 15
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​
Advanced Accelerator
GenSci139, a highly differentiated EGFR×HER2 Applications SA, Novartis
April 27, 2025, 02:00 PM - 5:00 PM,
340 / 7 bispecific ADC, for the treatment of multiple solid GenSci139 Pharmaceuticals AG, EGFR, HER-2
Section 16
tumors Telix Pharmaceuticals
Ltd
VBC108: a first-in-class CDH17/CLDN18.2
targeted bispecific antibody drug conjugate (ADC) April 27, 2025, 02:00 PM - 5:00 PM,
341 / 8 VBC108 VelaVigo CDH17, CLDN18.2
to overcome tumor heterogeneity of Section 16
gastrointestinal cancers (GC, PADC, CRC, etc.)

GenSci143, a novel B7-H3×PSMA bispecific and

April 27, 2025, 02:00 PM - 5:00 PM,
343 / 10 potential best-in-class ADC, for the treatment of GenSci143 VelaVigo B7-H3, PSMA
Section 16
metastatic castration-resistant prostate cancer
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

MP0712, the first anti-DLL3 212Pb radio-DARPin OranoMed; Molecular

April 27, 2025, 02:00 PM - 5:00 PM,
346 / 13 (RDT) candidate for targeted radiotherapy of small MP0712 Partners AG; Novartis DLL3
Section 16
cell lung cancer (SCLC) Pharmaceuticals AG

Novel EGFR x cMET bispecific ADC GQ1033 and GQ1033 c-MET, EGFR
Genequantum April 27, 2025, 02:00 PM - 5:00 PM,
347 / 14 DLL3-ADC GQ1030 demonstrated promising
Healthcare Section 16
therapeutic efficacy in preclinical studies GQ1030 DLL3

Development of an anti-TF ADC with a potentially Integrin beta-6, PD- April 27, 2025, 02:00 PM - 5:00 PM,
348 / 15 JSKN022 Alphamab Oncology
improved therapeutic index L1 Section 16
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical development of MHB042C: A next-

generation anti-c-Met ADC conjugating VHH-Fc Minghui Pharmaceutical April 27, 2025, 02:00 PM - 5:00 PM,
352 / 19 MHB042C c-MET
fusion protein with a novel topoisomerase I (Hangzhou) Co Ltd Section 16
inhibitor

Preclinical development of MHB048C: A novel

Minghui Pharmaceutical April 27, 2025, 02:00 PM - 5:00 PM,
353 / 20 anti-PSMA ADC with a potent topoisomerase I MHB048C PSMA
(Hangzhou) Co Ltd Section 16
inhibitor

TRX-214-1002, An antibody drug conjugate

Therapex Corp.
(ADC) targeting CD33 with a novel GSPT1 April 27, 2025, 02:00 PM - 5:00 PM,
382 / 1 TRX-214 (Interpark Bio SIGLEC3
molecular glue for treatment of acute myeloid Section 18
Convergence)
leukemia
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

MUC1*-deruxtecan kills tumors that have acquired Minerva Anti MUC1 April 27, 2025, 02:00 PM - 5:00 PM,
558 / 20 Minerva Biotechnologies MUC1*
resistance to trastuzumab containing therapeutics ADC Section 24

CHU de Quebec-
Effectiveness of [ 225 Ac]Ac-labeled anti-MUC-16
[225Ac]Ac- Universite April 27, 2025, 02:00 PM - 5:00 PM,
567 / 2 radioimmunconjugate against CA125 expressing MUC16
Macropa-MUC-16 Laval,University of Section 25
pancreatic and ovarian cancer xenografts
Saskatchewan

Discovery of FL801, a B7-H3-targeting nanobody-

Full Life Technologies April 27, 2025, 02:00 PM - 5:00 PM,
576 / 11 based radioligand vector, using Clear-XTM linker [177Lu]Lu-FL801 B7-H3
(HK) Ltd. Section 25
technology

ATNM-400 is a novel Actinium-225 antibody

Actinium April 27, 2025, 02:00 PM - 5:00 PM,
578 / 13 radioconjugate with strong efficacy in preclinical ATNM-400 Undisclosed
Pharmaceuticals, Inc. Section 25
models of prostate cancer
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

111 In/ 225 Ac-ABD320, a novel 5T4-targeted

radiopharmaceutical with favorable tumor-to- April 27, 2025, 02:00 PM - 5:00 PM,
580 / 15 225 Ac-ABD320 Abdera Therapeutics Inc. 5T4
normal tissue biodistribution and single-dose Section 25
efficacy in preclinical cancer models
[225Ac]Ac-
Macropa-
pertuzumab-PEG6-
Better together: Biparatopic [225 Ac]Ac-labeled DM1
anti-HER2 antibody-drug radioconjugates using [225Ac]Ac-
University of April 27, 2025, 02:00 PM - 5:00 PM,
581 / 16 two domain-specific antibodies for the treatment macropa- HER-2
Saskatchewan Section 25
of trastuzumab and T-DM1 resistant HER2- trastuzumab-PEG6-
positive breast cancer xenografts DM1
[225Ac]Ac-
Macropa-(T+P)-
PEG6-DM1)
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

AdvanCell Isotopes Pty

588 / 23 - Preclinical evaluation of a novel 212 Pb-
[212Pb]Pb- Limited; Eli Lilly and April 27, 2025, 02:00 PM - 5:00 PM,
588 / 23 based, PSMA-targeted radioligand, 212 Pb- PSMA
ADVC001 Company; POINT Section 25
ADVC001, for prostate cancer treatment
Biopharma Inc
Advanced Accelerator
Prostate specific membrane antigen targeted Applications SA, Novartis
April 27, 2025, 02:00 PM - 5:00 PM,
590 / 25 PRMT5 inhibition re-sensitizes cancer cells to 177Lu-Pluvicto Pharmaceuticals AG, PSMA
Section 25
radiation therapies Telix Pharmaceuticals
Ltd

Actinium ( 225Ac ) Actinium

Lintuzumab-Ac225 has potent mutation agnostic April 27, 2025, 02:00 PM - 5:00 PM,
594 / 29 lintuzumab Pharmaceuticals, Inc.; SIGLEC3
antileukemic activity in preclinical models of AML Section 25
satetraxetan Columbia University
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

AZD5335, a folate receptor alpha-targeted ADC,

Folate Receptor April 27, 2025, 02:00 PM - 5:00 PM,
815 / 3 enhances ovarian cancer treatment with AZD5335 AstraZeneca PLC
Alpha Section 34
bevacizumab, paclitaxel and/or carboplatin

Combined a B7-H3-targeting antibody-drug

conjugate, 7MW3711, and PARP inhibitors Mabwell (Shanghai) April 27, 2025, 02:00 PM - 5:00 PM,
830 / 18 7MW3711 B7-H3
synergistically potentiates the antitumor activity in Bioscience Co Ltd Section 34
B7-H3-positive cancers

Taipei Medical
A novel anti-CEACAM6 heavy-chain antibody- April 27, 2025, 02:00 PM - 5:00 PM,
833 / 21 University HCAb- Taipei Medical University CEACAM6
drug conjugate for gastrointestinal cancer therapy Section 34
ADC
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Antitumor effect and underlying mechanism on

Patritumab Novartis Pharmaceuticals April 27, 2025, 02:00 PM - 5:00 PM,
LB012 / 12 DNA damage response in breast cancer cells HER-3
Deruxtecan AG, PeptiDream Inc. Section 50
treated with HER3-DXd

TJ102: A promising bispecific dual-payload ADC

April 27, 2025, 02:00 PM - 5:00 PM,
LB021 / 21 targeting CDH6 and folate receptor alpha () for the TJ102 Phrontline Biopharma CDH6; FRα
Section 50
treatment of ovarian and kidney cancers

Preclinical characterization of AZD0516, a novel

April 27, 2025, 03:10 PM - 3:25:00
1158 STEAP2 antibody-drug conjugate (ADC) for the AZD0516 AstraZeneca PLC STEAP2
PM
treatment of prostate cancer

Preclinical characterization of a novel STEAP1

April 27, 2025, 03:25 PM - 3:40:00
1159 antibody-drug conjugate ADRX-0405 for the ADRX-0405 Adcentrx Therapeutics STEAP-1
PM
treatment of mCRPC
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

In silico optimized NAMPT inhibitor for targeted

delivery by antibody drug conjugates as novel Heidelberg Pharma
1162 Heidelberg Pharma CD30, HER-2 April 27, 2025, 04:10 PM - 4:25 PM
therapeutic modality for treatment of liquid and ADC
solid malignancies

Preclinical investigation of ADCT-242, a novel

exatecan-based antibody drug conjugate targeting
1163 ADCT-242 ADC Therapeutics S.A. CLDN6 April 27, 2025, 04:25 PM - 4:40 PM
Claudin-6, as single agent or in combination in
ovarian and non-small lung cancer models

SOT106, a novel best-in-class antibody-drug SOTIO Biotech;

1164 conjugate targeting LRRC15, to treat sarcomas SOT106 LigaChem Biosciences LRRC15 April 27, 2025, 04:40 PM - 4:55 PM
and other advanced solid cancers Inc

An isogeneic Trop-2 expression heterogeneity

April 28, 2025, 09:00 AM - 12:00
1270 / 3 model for evaluating the bystander killing effect of WuXi AppTec ADC WuXi AppTec Limited TROP-2
PM, Section 3
anti-Trop-2 ADC
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Clinical relevance and translatability of NSCLC

Champions anti- April 28, 2025, 09:00 AM - 12:00
1287 / 20 patient-derived xenograft (PDX) models for Champions Oncology CMET
cMET ADC PM, Section 3
evaluating cMET-targeted therapies

Trastuzumab Genentech, Inc.; April 28, 2025, 09:00 AM - 12:00

HER-2
emtansine Hoffmann-La Roche AG PM, Section 3
A translational approach to ADC evaluation:
1295 / 28 preclinical single-mouse basket trial with Bayesian
modelling analysis AstraZeneca PLC;
Trastuzumab April 28, 2025, 09:00 AM - 12:00
Daiichi Sankyo, Inc.; HER-2
deruxtecan PM, Section 3
Alteogen, Inc.

BPGbio Inc; Berg, LLC;

Reversal of the Warburg Effect with BPM31510
Stanford University April 28, 2025, 09:00 AM - 12:00
1527 / 9 treatment in a quinone deficient C6 Glioma BPM31510 Undisclosed
School of Medicine; PM, Section 14
resulting in efficacy
Columbia University
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

SCR-A0011, a novel bispecific ADC targeting

Simcere Pharmaceutical April 28, 2025, 09:00 AM - 12:00
1560 / 9 cMET and B7H3, exhibits potent anti-tumor SCR-A0011 B7-H3, CMET
Group PM, Section 15
efficacy

Antitumor effect of farletuzumab ecteribulin in Morphotek Inc; Eisai,

Farletuzumab Folate Receptor April 28, 2025, 09:00 AM - 12:00
1561 / 10 molecular subtypes of endometrial cancer patient- Inc.; Bristol-Myers
Ecteribulin Alpha PM, Section 15
derived xenograft models Squibb

ADRX-0134 as a novel auristatin-based NaPi2b

April 28, 2025, 09:00 AM - 12:00
1563 / 12 antibody-drug conjugate with widened therapeutic ADRX-0134 Adcentrx Therapeutics NaPi2b
PM, Section 15
window
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

MW-C1, a novel CLDN1-targeting ADC

Mabwell (Shanghai) April 28, 2025, 09:00 AM - 12:00
1573 / 22 demonstrates compelling anti-tumor efficacy and MW-C1 CLDN1
Bioscience Co Ltd PM, Section 15
favorable safety profile in preclinical studies

PF-08046876: A new camptothecin antibody-drug

conjugate directed to integrin beta-6 with potent April 28, 2025, 09:00 AM - 12:00
1577 / 26 PF-08046876 Pfizer Inc Integrin beta-6
antitumor activity in multiple preclinical solid tumor PM, Section 15
models

Preclinical evaluation of BLB-101, a

topoisomerase-inhibitor-based anti-CLDN6/9 April 28, 2025, 09:00 AM - 12:00
1578 / 27 BLB-101 Baylink Biosciences Inc. CLDN6, CLDN9
antibody-drug conjugate featuring a proprietary PM, Section 15
hydrophilic linker
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

KH815, a novel dual-payload TROP2-directed

Chengdu Kanghong April 28, 2025, 09:00 AM - 12:00
1586 / 2 antibody-drug conjugate, shows potent antitumor KH815 TROP-2
Biotechnology Co., Ltd. PM, Section 16
efficacy in pre-clinical tumor model

A novel dual-payload HER3-directed antibody- Chengdu Kanghong

April 28, 2025, 09:00 AM - 12:00
1587 / 3 drug conjugate, shows potent antitumor efficacy in KHN922 Pharmaceutical Group HER-3
PM, Section 16
HER3-low in vivo tumor models Co., Ltd.

BPGbio Inc; Berg, LLC;

Mechanisms of BPM31510-induced cell death in Stanford University April 28, 2025, 09:00 AM - 12:00
1591 / 7 BPM31510 Undisclosed
cancer: lipid peroxidation and apoptosis pathways School of Medicine; PM, Section 16
Columbia University
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Investigating trastuzumab-deruxtecan (DS-8201)

AstraZeneca PLC;
resistance mechanisms using clinically relevant Trastuzumab April 28, 2025, 09:00 AM - 12:00
1701 / 2 Daiichi Sankyo, Inc.; HER-2
PDX models and combination strategies with anti- deruxtecan PM, Section 20
Alteogen, Inc.
PD-1 antibody

OBI-992, a novel TROP2 antibody-drug

April 28, 2025, 09:00 AM - 12:00
1702 / 3 conjugate, exhibits distinct resistance profiles OBI-992 OBI Pharma; Biosion Inc. TROP-2
PM, Section 20
compared to other TROP2 targeting ADCs

Overcoming resistance in HER2-positive gastric

and breast cancers: Efficacy of disitamab vedotin RemeGen Co Ltd; Pfizer April 28, 2025, 09:00 AM - 12:00
1704 / 5 Disitamab vedotin HER-2
in preclinical models resistant to trastuzumab Inc; Seagen Inc. PM, Section 20
emtansine and trastuzumab deruxtecan
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

AstraZeneca PLC;
Understanding ADC resistance using preclinical Trastuzumab April 28, 2025, 09:00 AM - 12:00
1714 / 15 Daiichi Sankyo, Inc.; HER-2
enhertu-induced resistant models deruxtecan PM, Section 20
Alteogen, Inc.

Acquired cell adhesion molecule 1 (CADM1) ADC UT MD Anderson

MD Anderson Cancer April 28, 2025, 09:00 AM - 12:00
1716 / 17 resistance model for optimizing payload efficacy Cancer Center CADM1
Center PM, Section 20
and toxicity in osteosarcoma preclinical testing CADM1 ADC

SYNB011128: A novel bispecific peptide-drug- April 28, 2025, 09:00 AM - 12:00

1761 / 13 SYNB011128 Syneron Bio CA9, EGFR
conjugate targeting EGFR and CAIX PM, Section 22
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical development of TGW101, a first in

Tagworks April 28, 2025, 09:00 AM - 12:00
1794 / 13 class click-cleavable ADC with MMAE against TGW101 TAG-72
Pharmaceuticals PM, Section 23
non-internalizing pan-carcinoma marker TAG72

K-679: A novel, ultra-high-DAR antibody drug-

loaded unimicelle conjugate (ADUC) enabling April 28, 2025, 09:00 AM - 12:00
1798 / 17 K-679 EGFR
more effective treatment in EGFR-expressing Kowa Company, Ltd. PM, Section 23
solid tumors compared to general ADCs

OBI-902 TROP-2
Harnessing the GlycOBI® enabling technologies:
April 28, 2025, 09:00 AM - 12:00
1799 / 18 next-generation site-specific glycan ADCs with OBI Pharma
PM, Section 23
versatile DAR to enhance therapeutic index
OBI-904 Nectin-4
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

An innovative dual-payload ADC combining MediLink Therapeutics

MediLink Dual April 28, 2025, 09:00 AM - 12:00
1804 / 23 topoisomerase 1 inhibitor and a tubulin inhibitor (Suzhou) Co., Ltd (Yilian HER-2
Payload ADC PM, Section 23
efficiently overcomes drug resistance Biotechnology)

IMD2126 PD-L1

Shanghai Affinity April 28, 2025, 9:00 AM - 12:00 PM,

1805 / 24 Dual-payload TME-activated ADC platform IMD526 HER-2
Biopharmaceutical Co., Section 23
Ltd.
IMD-2113 PD-L1

Cymirafen: A protein-drug conjugate that target April 28, 2025, 09:00 AM - 12:00
1806 / 25 Cymirafen Moores Cancer Center LGR5
LGR4/LGR5/LGR6-positive cancer stem cells PM, Section 23
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

SIM0680, a potent antibody-drug conjugate for the Hainan Simcere Zaiming April 28, 2025, 09:00 AM - 12:00
2115 / 1 SIM0680 ENPP3
treatment of solid tumors expressing ENPP3 Biologics Co., Ltd PM, Section 34

ImmunoGen, Inc.;
Targeting KIT in chromophobe renal cell April 28, 2025, 09:00 AM - 12:00
2119 / 5 LOP628 Novartis Pharmaceuticals cKIT
carcinoma PM, Section 34
AG; AbbVie Ltd

Uncovering the multiple therapeutic mechanisms

AstraZeneca PLC;
of trastuzumab deruxtecan (T-DXd): effective Trastuzumab April 28, 2025, 09:00 AM - 12:00
2128 / 14 Daiichi Sankyo, Inc.; HER-2
extracellular payload release and deruxtecan PM, Section 34
Alteogen, Inc.
immunomodulatory stimulation
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

KA-2886-LD38: a bispecific antibody-drug

KYinno Biotechnology,
conjugate (ADC) targeting both EGFR and MET, April 28, 2025, 09:00 AM - 12:00
2134 / 20 KA-2886-LD38 Shanghai Escugen c-MET, EGFR
incorporating a novel linker-payload that inhibits PM, Section 34
Biotechnology Co Ltd
DNA topoisomerase I

ALG01, a next-generation anti-PD-L1×TROP-2

bispecific antibody-drug conjugate (BiADC) with April 28, 2025, 09:00 AM - 12:00
2138 / 24 ALG01 Allygen Biologics PD-L1, TROP-2
STAR technology, demonstrated excellent anti- PM, Section 34
tumor efficacy & safety in preclinical studies

Trastuzumab deruxtecan induces immunogenic AstraZeneca PLC;

Trastuzumab April 28, 2025, 09:00 AM - 12:00
2160 / 14 cell death, immune cell activation and -migration Daiichi Sankyo, Inc.; HER-2
deruxtecan PM, Section 35
in viable human breast cancer slices Alteogen, Inc.
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Development of an anti-TF ADC with a potentially GenFleet Therapeutics April 28, 2025, 09:00 AM - 12:00
LB136 / 15 GFS784 EGFR
improved therapeutic index Inc. PM, Section 52

April 28, 2025, 10:20 AM - 10:35:00

BAY 3547926: Novel targeted radionuclide
ND09 BAY 3547926 Bayer Undisclosed AM, Room S406 (Vista Ballroom) -
therapy for hepatocellular carcinoma
McCormick Place South (Level 4)

Biodistribution and dosimetry of FAPI-46 in mouse 3B Pharmaceuticals

April 28, 2025, 02:00 PM - 5:00 PM,
2540 / 19 model of colorectal carcinoma with PET and FAPI-46 GmbH; Clovis Oncology, FAP
Section 1
SPECT imaging Inc.
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Anti MSLN ADC RC88 engages unique binding to

April 28, 2025, 02:00 PM - 5:00 PM,
2862 / 1 target positive tumor cells with less interference Misitatug blivedotin RemeGen Co Ltd Mesothelin (MSLN)
Section 15
from the soluble MSLN protein

TAVO307, a novel ADC targeting CDH17, for the April 28, 2025, 02:00 PM - 5:00 PM,
2863 / 2 TAVO307 Tavotek Biotherapeutics CDH17
therapy of gastrointestinal cancers Section 15

DXA023-G017, a bispecific PD-1/VEGF conjugate

Hangzhou DAC April 28, 2025, 02:00 PM - 5:00 PM,
2864 / 3 elicits potent anti-tumor efficacy in preclinical DXA023-G017 PD-1, VEGF
Biotechnology Co Ltd Section 15
studies

Preclinical evaluation of LM-350: An innovative

LaNova Medicines April 28, 2025, 02:00 PM - 5:00 PM,
2868 / 7 anti-CDH17 antibody drug conjugate for LM-350 CDH17
Limited Section 15
gastrointestinal cancer therapy
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

STRO-00X Topo1i
+ anti-Tubulin Dual-
Enhancing Topo1i ADC efficacy: development of payload ADC HER-2
homogeneous dual-payload ADCs combining April 28, 2025, 02:00 PM - 5:00 PM,
2870 / 9 Sutro Biopharma, Inc.
Topo1i with microtubule inhibitors or PARP Section 15
STRO-00X Topo1i
inhibitors
+ PARPi Dual-
payload ADC Tissue factor

Comparative anti-tumoral efficacy of endoglin- OMTX603-3

Oncomatryx Biopharma April 28, 2025, 02:00 PM - 5:00 PM,
2871 / 10 targeting ADCs harbouring different payloads for Endoglin
SL Section 15
the treatment of gastric cancer OMTX103

DXC018: A novel HER2 dual-payload bispecific

Hangzhou DAC April 28, 2025, 02:00 PM - 5:00 PM,
2872 / 11 ADC with promising potential for gastrointestinal DXC-018 Undisclosed
Biotechnology Co Ltd Section 15
cancers and other solid tumors
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

IL1RAP-targeting antibody-drug conjugate: a

Cantargia AB anti- AbbVie Ltd, Cantargia April 28, 2025, 02:00 PM - 5:00 PM,
2875 / 14 novel therapeutic targeting both tumor cells and IL1RAP
IL1RAP ADC AB Section 15
the tumor microenvironment

BR116: An antibody drug conjugate targeting BioRay Pharmaceutical April 28, 2025, 02:00 PM - 5:00 PM,
2876 / 15 BR116 CDH17
CDH17 for gastrointestinal cancer therapy Co., Ltd. Section 15

MRG007, a cadherin 17-targeted, glycan-linked,

Shanghai Miracogen Inc.
exatecan-based antibody-drug conjugate, April 28, 2025, 02:00 PM - 5:00 PM,
2877 / 16 MRG007 (Shanghai Meiya Undisclosed
demonstrated potent anti-tumor activity and a Section 15
Biotechnology Co., Ltd)
good safety profile in preclinical studies
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

QLS5133-a novel CDH6-targeting antibody-drug- Qilu Pharmaceutical Co April 28, 2025, 02:00 PM - 5:00 PM,
2881 / 20 QLS5133 CDH6
conjugate for solid tumors Ltd Section 15

Development and preclinical characterization of ChemPartner

Shanghai ChemPartner April 28, 2025, 02:00 PM - 5:00 PM,
2882 / 21 HER2×Trop-2 bispecific antibody-drug conjugates HER2×Trop-2 HER-2, TROP-2
Co., Ltd. Section 15
(bsADCs) with auristatin microtubule inhibitors Bispecific ADC

Cetuximab increases LGR5 expression and

enhances efficacy of LGR5 antibody-drug UT Health Houston- April 28, 2025, 02:00 PM - 5:00 PM,
2883 / 22 UT Health Houston LGR5
conjugates in patient-derived models of colorectal LGR5 ADC Section 15
cancer

IKS04, an antibody drug conjugate with a highly Iksuda Therapeutics

April 28, 2025, 02:00 PM - 5:00 PM,
2885 / 24 potent DNA crosslinker payload for the treatment IKS04 (Glythera Ltd); LigaChem CA242
Section 15
of gastrointestinal cancers Biosciences Inc
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​
Juntendo
Anti-tumor effect and mechanism of action of a
University,Saitama
nuclear transportable antibody drug conjugate Y- April 28, 2025, 02:00 PM - 5:00 PM,
2890 / 29 Y-TR-1 Medical University DPP4
TR-1: Anti CD26 antibody conjugated with RNA Section 15
International Medical
polymerase II inhibitor triptolide
Center

Trastuzumab Genentech, Inc.;

In vitro comparison of Kadcyla and Enhertu in
emtansine Hoffmann-La Roche AG
breast cancer with varying HER2 expression: April 28, 2025, 02:00 PM - 5:00 PM,
2891 / 30 HER-2
proliferation, internalization, bystander effects and AstraZeneca PLC; Section 15
toxicity Trastuzumab
Daiichi Sankyo, Inc.;
deruxtecan
Alteogen, Inc.
CS2011: A novel bispecific antibody targeting
CStone Pharmaceuticals April 28, 2025, 02:00 PM - 5:00 PM,
2927 / 1 EGFR and HER3 that demonstrates promising CS5007 EGFR, HER-3
Co., Ltd. Section 17
antitumor activity in preclinical evaluation
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

GNX1021, a novel ADC targeting glycans with

branched Lewis B/Y, demonstrated preclinical April 28, 2025, 02:00 PM - 5:00 PM,
2932 / 6 GNX1021 GlycoNex Glycan
tumor control activity in gastric cancer models and Section 17
favorable safety

IDP-001 is a potent bispecific ADC with in vivo

April 28, 2025, 02:00 PM - 5:00 PM,
2933 / 7 activity against mouse xenograft tumor models IDP-001 InduPro Inc EGFR
Section 17
expressing EGFR and CDCP1

Novel hydrophilic CDH17-targeting antibody-drug

Nanjing Leads Biolabs April 28, 2025, 02:00 PM - 5:00 PM,
2934 / 8 conjugate exhibits anti-tumor efficacy in preclinical LBL-054 CDH17
Co Ltd Section 17
xenograft models
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

SWY2321, a novel topoisomerase I inhibitor

CSPC Pharmaceutical April 28, 2025, 02:00 PM - 5:00 PM,
2943 / 17 linked bispecific ADC targeting EGFR/cMet, SWY2321 CMET, EGFR
Group Limited Section 17
exhibits potent anti-tumor efficacy

Synergistic lethality of combination treatment with

Gilead Sciences; Everest
Trop2-directed antibody-drug conjugate (IMMU- Sacituzumab April 28, 2025, 02:00 PM - 5:00 PM,
2944 / 18 Medicines Ltd; TROP-2
132) and Apo2L/TRAIL in triple negative breast govitecan Section 17
Immunomedics Inc
cancer (TNBC)

PLB-002 is a novel Claudin 6 antibody-drug

PrimeLink April 28, 2025, 02:00 PM - 5:00 PM,
2945 / 19 conjugate for ovarian cancer and testicular germ PLB-002 Claudin 6
BioTherapeutics Section 17
cell cancer

Trastuzumab Genentech, Inc.;

Receptor quantification in the context of human emtansine Hoffmann-La Roche AG
April 28, 2025, 02:00 PM - 5:00 PM,
1564 / 13 epidermal growth factor receptor 2 (HER2) HER-2
AstraZeneca PLC; Section 18
antibody-drug conjugates Trastuzumab
Daiichi Sankyo, Inc.;
deruxtecan
Alteogen, Inc.
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Trastuzumab Genentech, Inc.; April 28, 2025, 02:00 PM - 5:00 PM,

HER-2
emtansine Hoffmann-La Roche AG Section 18
Identification of sensitivity predictors and
2950 / 2
differentiators for HER2-directed ADCs
AstraZeneca PLC;
Trastuzumab April 28, 2025, 02:00 PM - 5:00 PM,
Daiichi Sankyo, Inc.; HER-2
deruxtecan Section 18
Alteogen, Inc.

CS5006: A novel integrin β4-targeted antibody-

CStone Pharmaceuticals April 28, 2025, 02:00 PM - 5:00 PM,
2953 / 5 drug conjugate (ADC) with robust antitumor CS5006 ITGB4
Co., Ltd. Section 18
activity in preclinical studies

CS5007: A novel EGFR and HER3 dual-targeted

CStone Pharmaceuticals April 28, 2025, 02:00 PM - 5:00 PM,
2954 / 6 antibody-drug conjugate (ADC) with potent CS5007 EGFR, HER-3
Co., Ltd. Section 18
antitumor activity in preclinical studies
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Establishing preclinical activity of topoisomerase I

inhibitor (TOPO1i) antibody-drug conjugate
Tilatamig April 28, 2025, 02:00 PM - 5:00 PM,
2957 / 9 AZD9592 in patient-derived xenograft (PDX) AstraZeneca PLC c-MET, EGFR
samrotecan Section 18
models of metastatic colorectal cancer (mCRC) in
context of irinotecan pretreatment and resistance

PF-08046031: A promising first-in-class antibody-

April 28, 2025, 02:00 PM - 5:00 PM,
2959 / 11 drug conjugate for targeting novel tumor antigen PF-08046031 Pfizer Inc CD228
Section 18
in melanoma

MYTX-011: A pH-dependent anti-cMET ADC

exhibits potent activity in multiple epithelial tumor April 28, 2025, 02:00 PM - 5:00 PM,
2960 / 12 MYTX-011 Mythic Therapeutics c-MET
models with clinically actionable mutations and Section 18
varying levels of cMET expression
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

SCR-A006, an innovative and potential best-in-

Nanjing Zaiming April 28, 2025, 02:00 PM - 5:00 PM,
2965 / 17 class EGFR/cMet bispecific antibody-drug SCR-A006 c-MET, EGFR
Pharmaceutical Co., Ltd. Section 18
conjugate

The anti-tumor activity of a novel anti-Her2 and April 28, 2025, 02:00 PM - 5:00 PM,
2966 / 18 BB-205 Bright Biologics LLC HER-2, Undisclosed
anti-c-Met bispecific antibody-drug conjugate Section 18

AstraZeneca PLC;
Trastuzumab
Daiichi Sankyo, Inc.;
Characterization of targeted ADC and small deruxtecan
Alteogen, Inc. April 28, 2025, 02:00 PM - 5:00 PM,
2971 / 1 molecule therapy efficacy toward HER2-mutated HER-2
Section 19
XPDX models Trastuzumab Genentech, Inc.;
emtansine Hoffmann-La Roche AG
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Evaluation of PYX-201, an EDB+FN-targeting

ADC, in a comprehensive PDX mini-trial study Micvotabart Pfizer Inc; Pyxis Fibronectin extra- April 28, 2025, 02:00 PM - 5:00 PM,
3120 / 5
enables identification of gene signatures pelidotin Oncology domain B Section 24
associated with anti-tumor activity

Innovative development of IMB-201, an anti-HLA-

Human leukocyte April 28, 2025, 02:00 PM - 5:00 PM,
3132 / 17 G antibody-drug conjugate (ADC), for enhanced IMB-201 IMBiologics Corp
antigen G Section 24
tumor immunotherapy

PF-08046032: a CD25-directed vedotin ADC

leveraging a well characterized safety and April 28, 2025, 02:00 PM - 5:00 PM,
3133 / 18 PF-08046032 Pfizer Inc IL-2R Alpha
pharmacokinetic profile for enhanced regulatory T Section 24
cell depletion in the tumor microenvironment

The combination of anti-PD1 and a mouse analog

of PYX-201, an antibody-drug conjugate targeting
Micvotabart Pfizer Inc; Pyxis Fibronectin extra- April 28, 2025, 02:00 PM - 5:00 PM,
3137 / 4 the extra-domain B splice variant of fibronectin
pelidotin Oncology domain B Section 24
(EDB+FN), shows greater anti-tumor efficacy than
either treatment alone
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical development of YL242, a non-

MediLink Therapeutics
internalized antibody-drug conjugate (ADC) April 28, 2025, 02:00 PM - 5:00 PM,
3140 / 25 YL242 (Suzhou) Co., Ltd (Yilian VEGF
targeting soluble VEGF for treatment of solid Section 24
Biotechnology)
tumors

OMTX705: A dual-mechanism ADC targeting

Oncomatryx Biopharma April 28, 2025, 02:00 PM - 05:00
6391 / 30 FAP-positive CAFs, to overcome chemo and OMTX705 FAP
SL; InxMed Co., Ltd. PM, Section 24
immunotherapy resistance in solid tumors

Advanced Accelerator
IND enabling study of NRT-YHD_001, a Applications SA, Novartis
April 28, 2025, 02:00 PM - 5:00 PM,
3209 / 5 macrophage immune checkpoint inhibitor in liver NRT-YHD_001 Pharmaceuticals CD47, Undisclosed
Section 28
cancer AG, Telix
Pharmaceuticals Ltd
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical studies of BR-2302: A HER3xEGFR bi- Bliss Biopharmaceutical April 28, 2025, 02:00 PM - 5:00 PM,
3417 / 12 BR-2302 EGFR, HER-3
specific Exd-containing ADC Co., Ltd. Section 35

Engineering and construction of anti-B7-H3

antibody-based T cell engagers (TCEs) and Helixon Anti-B7-H3 April 28, 2025, 02:00 PM - 5:00 PM,
3499 / 7 Helixon B7-H3
antibody-drug conjugates (ADCs) for cancer ADC Section 38
therapy

Preclinical characterization of IBI3010, a FRα

targeting biparatopic antibody-drug conjugate Innovent Biologics Co. Folate Receptor April 28, 2025, 02:00 PM - 5:00 PM,
LB222 / 19 IBI3010
(ADC), for the treatment of FRα expressing Ltd. Alpha Section 53
tumors

ALM-401: A first-in-class next generation

Almac Discovery; April 28, 2025, 02:00 PM - 5:00 PM,
LB229 / 3 bispecific ADC configured to deliver superior ALM-401 EGFR, ROR1
Elasmogen Section 54
efficacy in selected solid tumor indications
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Datopotamab Daiichi Sankyo, Inc.;

TROP-2
deruxtecan AstraZeneca PLC
Preclinical assessment of valemetostat, a dual
inhibitor of EZH2 and EZH1, combined with
3790 April 28, 2025, 04:10 PM - 4:25 PM
trastuzumab deruxtecan and datopotamab
deruxtecan for multiple solid tumors AstraZeneca PLC;
Trastuzumab
Daiichi Sankyo, Inc.; HER-2
deruxtecan
Alteogen, Inc.

Organoids and immune cells co-culture for Astellas Pharma Inc;

April 29, 2025, 09:00 AM - 12:00
3996 / 12 evaluating the efficacy of enfortumab vedotin and Enfortumab vedotin Pfizer Inc; Seagen Inc.; Nectin-4
PM, Section 7
pembrolizumab combination therapy. Summit Therapeutics Inc

AstraZeneca PLC;
The role of NHEJ/HR mediated DSB repair in Trastuzumab April 29, 2025, 09:00 AM - 12:00
4188 / 5 Daiichi Sankyo, Inc.; HER-2
cancer cell sensitivity to payload of T-DXd ADC deruxtecan PM, Section 15
Alteogen, Inc.
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Membrane interactomics (MInt) platform identifies

April 29, 2025, 09:00 AM - 12:00
4255 / 12 EGFR and CDCP1 as effective co-targets for IDP-001 InduPro Inc EGFR, Undisclosed
PM, Section 17
bispecific antibody drug conjugate IDP-001

HY0001a: A novel antibody-drug conjugate (ADC)

Sichuan Huiyu April 29, 2025, 09:00 AM - 12:00
4256 / 13 targeting CUB domain containing protein 1 HY0001a CDCP1
Pharmaceutical Limited PM, Section 17
(CDCP1)

ADV-101: a novel ADC targeting IL-1RAP,

leveraging tumor cell and the tumor April 29, 2025, 09:00 AM - 12:00
4260 / 17 ADV-101 Advesya IL1RAP
microenvironment vulnerabilities for enhanced PM, Section 17
anti-tumor efficacy
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical development of SCR-A008: A CDH17- Nanjing Zaiming April 29, 2025, 09:00 AM - 12:00
4328 / 24 SCR-A008 CDH17
targeted ADC for gastrointestinal cancer Pharmaceutical Co., Ltd. PM, Section 19

GeneQuantum
Concomitant therapy leveraging antibody-pan- Healthcare
Genequantum April 29, 2025, 09:00 AM - 12:00
4332 / 28 KRAS mt siRNA conjugate for PDAC and LUAD (Suzhou) Antibody- KRAS, Undisclosed
Healthcare PM, Section 19
harboring KRAS mutations pan-KRASmt
siRNA Conjugate

SYS6051, a next-generation tissue factor-targeted

CSPC Pharmaceutical April 29, 2025, 09:00 AM - 12:00
4337 / 2 antibody-drug conjugates for the treatment of TF- SYS6051 Tissue factor
Group Limited PM, Section 20
expressing malignancies
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical evaluation, and clinical translation of 68 Bivision Biomedical

April 29, 2025, 09:00 AM - 12:00
4599 / 19 Ga/ 177 Lu-JH04, a novel FAP-targeting JH04 Technology (Nanjing) Undisclosed
PM, Section 30
radiolabeled agent Co., Ltd

Elucidating the mechanism of clinical Teliso-v

(cMet-MMAE ADC) and osimertinib combination: Telisotuzumab April 29, 2025, 09:00 AM - 12:00
4713 / 11 AbbVie Ltd c-MET
A CAV1 and EGFR multi-protein complex controls vedotin PM, Section 34
endolysosomal trafficking of Teliso-V

Development and preclinical activity of BSI-721, a

April 29, 2025, 09:00 AM - 12:00
4723 / 21 novel antibody-drug conjugate (ADC) targeting BSI-721 Biosion Inc. CDH17
PM, Section 34
cadherin 17 (CDH17) in gastrointestinal cancers
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Characterization of novel humanized FGFR2b

antibody-based ADCs site-specifically conjugated Suzhou Transcenta April 29, 2025, 09:00 AM - 12:00
4769 / 5 TST105 FGFR2b
with topoisomerase I inhibitor payload in Therapeutics Co., Ltd. PM, Section 36
preclinical tumor models

AI-guided engineering and preclinical

Helixon anti-DLL3 April 29, 2025, 09:00 AM - 12:00
4772 / 8 development of biparatopic anti-DLL3 antibody- Helixon CD3, DLL3
Biparatopic ADC PM, Section 36
drug conjugates (ADCs)

AM E3-SG3249, a first-in-class α-CRLF2

April 29, 2025, 09:00 AM - 12:00
4773 / 9 antibody-drug conjugate for the treatment of AM E3-SG3249 IRBM S.p.A. TSLPR
PM, Section 36
CRLF2-rearranged Ph-like B-ALL

Combination therapy with TB511 and anti-nectin-4

April 29, 2025, 09:00 AM - 12:00
4775 / 11 antibody drug conjugate in a human pancreatic TB511 Twinpig Biolab, Inc M2-like TAMs
PM, Section 36
cancer mouse model
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

ADCE-T02: A first-in-class topoisomerase-1

inhibitor based antibody drug conjugate against Biocytogen April 29, 2025, 09:00 AM - 12:00
4778 / 14 ADCE-T02 Tissue factor
tissue factor demonstrates excellent preclinical Pharmaceuticals Co Ltd PM, Section 36
efficacy and tolerability

Preclinical studies of BB-1705: An EGFR-

targeting eribulin-containing ADC with an affinity Bliss Biopharmaceutical April 29, 2025, 09:00 AM - 12:00
4779 / 15 BB-1705 EGFR
optimized antibody to minimize potential toxicities (Hangzhou) Co., Ltd. PM, Section 36
to normal tissues

Development and characterization of an antibody-

drug conjugate (ADC) utilizing PB-223, a novel Precision Biologics April 29, 2025, 09:00 AM - 12:00
4783 / 19 Precision Biologics core 2 O-glycan
monoclonal antibody (mAb) specifically targeting PB-223 ADC PM, Section 36
core 2 O-glycans on human carcinomas

ADCE-D01: a first in class antibody drug

conjugate against urokinase plasminogen
April 29, 2025, 09:00 AM - 12:00
4784 / 20 activator receptor-associated protein (uPARAP) ADCE-D01 ADCendo ApS MRC2
PM, Section 36
demonstrates excellent preclinical efficacy and
tolerability
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

BCG033: a first-in-class PTK7×TROP2 bispecific

Biocytogen April 29, 2025, 09:00 AM - 12:00
4793 / 29 ADC demonstrating potent and broad efficacy in BCG033 PTK7, TROP-2
Pharmaceuticals Co Ltd PM, Section 36
various preclinical models

CDH3-targeted ADC and CAR-T University of Notre

April 29, 2025, 09:00 AM - 12:00
4823 / 26 immunotherapies for metastatic double-negative Dame anti-CDH3 University of Notre Dame P-Cadherin
PM, Section 37
prostate cancer and triple-negative breast cancer ADC

LCB39, a novel systemically deliverable STING

LigaChem Biosciences April 29, 2025, 09:00 AM - 12:00
4882 / 10 agonist with strong preclinical activity and LCB39 STING, Undisclosed
Inc PM, Section 40
tolerability

SDP01873, a novel HER3×c-Met bispecific

antibody-drug conjugate (ADC) targeting EGFR
Shanghai Shengdi April 29, 2025, 09:00 AM - 12:00
LB279 / 2 tyrosine kinase inhibitor (TKI)-resistant non-small SDP01873 c-MET, HER3-ECD
Pharmaceutical Co., Ltd. PM, Section 52
cell lung cancer (NSCLC), colorectal cancer
(CRC) and beyond
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Exploring the clinical utility of HER2-targeted AstraZeneca PLC;

Trastuzumab April 29, 2025, 02:00 PM - 5:00 PM,
5189 / 4 antibody-drug conjugate in urothelial carcinoma Daiichi Sankyo, Inc.; HER-2
deruxtecan Section 4
using patient-derived models Alteogen, Inc.

IPH4502, a differentiated Nectin-4 exatecan April 29, 2025, 02:00 PM - 5:00 PM,
5443 / 1 IPH45 Innate Pharma Nectin-4
antibody-drug conjugate Section 15

Discovery and optimization of IDP-001, a April 29, 2025, 02:00 PM - 5:00 PM,
5445 / 3 IDP-001 InduPro Inc EGFR, Undisclosed
bispecific ADC targeting EGFR and CDCP1 Section 15
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Preclinical development of SCR-A003, a novel

Nanjing Zaiming April 29, 2025, 02:00 PM - 5:00 PM,
5449 / 7 topoisomerase I inhibitor-based antibody-drug SCR-A003 LIV-1
Pharmaceutical Co., Ltd Section 15
conjugate (ADC) targeting LIV-1 for solid cancer

JSKN022, a first in class multi-specific ADC

targeting PD-L1 and ITGB6/8 with an innovative
Inotuzumab April 29, 2025, 02:00 PM - 5:00 PM,
5450 / 8 DNA topoisomerase I inhibitor demonstrates Pfizer Inc SIGLEC2
ozogamicin Section 15
encouraging efficacy in preclinical models

JSKN021, an innovative site-specific dual-payload

April 29, 2025, 02:00 PM - 5:00 PM,
5451 / 9 bispecific antibody drug conjugate targeting EGFR JSKN021 Alphamab Oncology Undisclosed
Section 15
and HER3 exhibits potent preclinical activities
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

DB-1325, a BCMA-targeting antibody-drug

conjugate with a Duality Unique Payload, exhibits April 29, 2025, 02:00 PM - 5:00 PM,
5454 / 12 DB-1325 BCMA
promising efficacy and safety in preclinical DualityBio Inc. Section 15
multiple myeloma treatment

TAVO605, a novel CD318 (CDCP1) ADC, for the

April 29, 2025, 02:00 PM - 5:00 PM,
5455 / 13 treatment of solid cancers that are non- TAVO605 CDCP1
Tavotek Biotherapeutics Section 15
responding or resistant to Enhertu treatment

C6P, a claudin 6 (CLDN6) directed ADC

Shanghai Hengrui April 29, 2025, 02:00 PM - 5:00 PM,
5460 / 18 containing pyrolobenzodiazepine (PBD) for the C6P CLDN6
Pharmaceutical Co., Ltd. Section 15
treatment of advanced solid tumors
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

AMB304: A next generation ADC with topo I

inhibitor, demonstrating robust preclinical efficacy April 29, 2025, 02:00 PM - 5:00 PM,
5463 / 21 AMB304 Aimed Bio Inc. glycoprotein
against target overexpression tumors and high Section 15
tolerability in non-human primate (NHP)

7MW4911, a novel cadherin 17-targeting ADC,

Mabwell (Shanghai) April 29, 2025, 02:00 PM - 5:00 PM,
5466 / 24 demonstrates potent efficacy in preclinical models 7MW4911 CDH17
Bioscience Co Ltd Section 15
of gastrointestinal cancers

Therapeutic potential of antibody-drug conjugate

with PARP1 selective inhibitor as a payload: A April 29, 2025, 02:00 PM - 5:00 PM,
5467 / 25 Idience ADC Idience TROP-2
promising therapeutic approach for potent Section 15
antitumor efficacy with reduced toxicity

Crossfire Oncology
A novel kinase degrader antibody conjugate for Crossfire Oncology (Netherlands April 29, 2025, 02:00 PM - 5:00 PM,
5468 / 26 Undisclosed
the treatment of mCRPC DAC platform Translational Research Section 15
Center NTRC)
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​
AstraZeneca PLC;
Trastuzumab
Daiichi Sankyo, Inc.;
deruxtecan
In vitro real-time evaluation of bystander effects of Alteogen, Inc. April 29, 2025, 02:00 PM - 5:00 PM,
5476 / 4 HER-2
antibody-drug conjugates Section 16
Trastuzumab Genentech, Inc.;
emtansine Hoffmann-La Roche AG

Sacituzumab govitecan screening in a large

Gilead Sciences; Everest
organoid panel reveals the importance of Sacituzumab April 29, 2025, 02:00 PM - 5:00 PM,
5497 / 25 Medicines Ltd; TROP-2
functional assays for predicting ADC tumor govitecan Section 16
Immunomedics Inc
response

An integrated oligonucleotide synthesis and

Alnylam Pharmaceuticals
cellular in vitro assay platform to support April 29, 2025, 02:00 PM - 5:00 PM,
5502 / 30 Inclisiran Inc.; Novartis ASGPR, PCSK9
oligonucleotide-based drug discovery and Section 16
Pharmaceuticals AG
development
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

A novel in vivo self-assembled peptide-drug

April 29, 2025, 02:00 PM - 5:00 PM,
5646 / 24 conjugate targeting HER2 with potent anti-tumor iSAP-0913 Hisap HER-2
Section 21
efficacy overcoming resistance of HER2 ADCs

Discovery of a novel antibody-drug conjugate

HLX91-048-based Shanghai Henlius April 29, 2025, 02:00 PM - 5:00 PM,
5730 / 1 linker-payload with a distinct killing mechanism via HER-2
ADC Biotech, Inc. Section 25
prolonged unfolded protein response activation

BeiGene (Beijing)
BGB-C354, a novel B7H3 ADC with high DAR
Biotechnology Co., Ltd.;
stability and strong bystander effect, BeiGene B7-H3 April 29, 2025, 02:00 PM - 5:00 PM,
5731 / 2 Guangzhou BeiGene B7-H3
demonstrates robust antitumor activity in ADC Section 25
Biopharmaceutical Co.,
preclinical models
Ltd
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

PF-08046037, a PD-L1 targeted TLR7 agonist

ISAC, drives innate immune activation and anti- April 29, 2025, 02:00 PM - 5:00 PM,
5840 / 16 PF-08046037 Pfizer Inc PD-L1, TLR 7
tumor efficacy in preclinical in vitro and in vivo Section 29
models

AstraZeneca PLC;
Pertuzumab enhances the antitumor activity of T- Trastuzumab April 29, 2025, 02:00 PM - 5:00 PM,
5990 / 17 Daiichi Sankyo, Inc.; HER-2
DXd in HER2-positive gastric cancer cells deruxtecan Section 34
Alteogen, Inc.

Unveiling RYK: A breakthrough tumor-associated April 29, 2025, 02:00 PM - 5:00 PM,
6015 / 10 SLV-404 Solve Theraputics, Inc. RYK
antigen in lymphoma treatment Section 35
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

GFS202A, a novel GDF15×IL-6 bispecific GenFleet Therapeutics April 29, 2025, 02:00 PM - 5:00 PM,
6078 / 19 GFS202A GDF-15 , IL-6
antibody for the treatment of cachexia Inc. Section 37

Bispecific antibody drug conjugates (bsADCs)

Biocytogen
targeting DLL3 and B7-H3 demonstrated potent Biocytogen April 29, 2025, 02:00 PM - 5:00 PM,
6081 / 22 DLL3xB7H3 DLL3 , B7H3
anti-tumor activity in preclinical models of small Pharmaceuticals Co Ltd Section 37
bsADCs
cell lung cancer (SCLC)

Preclinical studies of BB-1712: A B7H3-targeting

eribulin-containing ADC with the potential to Bliss Biopharmaceutical April 29, 2025, 02:00 PM - 5:00 PM,
6173 / 25 BB-1712 B7-H3
overcome resistance to DNA topoisomerase I (Hangzhou) Co., Ltd. Section 40
inhibitor-containing ADCs
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Perivascular niche-resident alveolar macrophages AstraZeneca PLC;

Trastuzumab
6369 confer interstitial pneumonitis related to Daiichi Sankyo, Inc.; HER-2 April 29, 2025, 03:10 PM - 3:25 PM
deruxtecan
trastuzumab deruxtecan Alteogen, Inc.

E-cM-Topi, a potent EGFR-cMET bispecific

April 30, 2025, 09:00 AM - 12:00
6735 / 1 antibody drug conjugate, with superior anti-tumor E-cM-Topi Shanghai Hengrui c-MET, EGFR
PM, Section 16
effect in non-small-cell lung cancer (NSCLC) Pharmaceutical Co., Ltd.

Preclinical development of ADCT-241, a novel

April 30, 2025, 09:00 AM - 12:00
6736 / 2 exatecan-based antibody-drug conjugate targeting ADCT-241 ADC Therapeutics S.A. PSMA
PM, Section 16
PSMA for the treatment of prostate cancer

AstraZeneca PLC;
Antibody-drug conjugates with novel payloads are Trastuzumab April 30, 2025, 09:00 AM - 12:00
6739 / 5 Daiichi Sankyo, Inc.; HER-2
enabled by an ultra-high DAR platform deruxtecan PM, Section 16
Alteogen, Inc.
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

High-affinity human IgG1 antibody against

Hangzhou DAC April 30, 2025, 09:00 AM - 12:00
6742 / 8 GUCY2C for ADC development: Identification, DXC022 GUCY2C
Biotechnology Co Ltd PM, Section 16
characterization, and efficacy

Multi-modal assessment of an anti-HER2

Trastuzumab Genentech, Inc.; April 30, 2025, 09:00 AM - 12:00
6746 / 12 (trastuzumab) antibody-drug conjugate screening HER-2
emtansine Hoffmann-La Roche AG PM, Section 16
assay for breast cancer models

A next generation ADC: AR153, pH-dependent April 30, 2025, 09:00 AM - 12:00
6747 / 13 AR153 Y-Biologics B7-H3
anti-B7H3 MMAE PM, Section 16
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Discovery of the synergistic dual-payload

April 30, 2025, 09:00 AM - 12:00
6755 / 21 antibody-drug conjugate (CTPH-02) by CTPH-02 Celltrion HER-2
PM, Section 16
combination of MMAE and novel payloads

SYS6041, a next-generation Folate Receptor α-

CSPC Pharmaceutical April 30, 2025, 09:00 AM - 12:00
6832 / 17 targeted antibody-drug conjugates for the SYS6041 Folate Receptor α
Group Limited PM, Section 19
treatment of FRα-expressing malignancies

Development of a humanized C3 mouse model for

Arrowhead April 30, 2025, 09:00 AM - 12:00
6848 / 9 preclinical evaluation of therapeutics in C3 ARO-C3 Undisclosed
Pharmaceuticals PM, Section 20
glomerulopathy
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Discovery and characterization of DAC-1522, a

April 30, 2025, 09:00 AM - 12:00
7005 / 5 novel Trop2-targeting degrader-antibody DAC-1522 DaCure Therapeutics TROP-2
PM, Section 26
conjugate for precision oncology
The B7-H3 targeting antibody-drug conjugate
(ADC) vobramitamab duocarmazine (vobra duo)
is potently effective against a broad panel of Vobramitamab MacroGenics Inc; April 30, 2025, 09:00 AM - 12:00
7040 / 10 B7-H3
pediatric solid tumor xenograft models: A study duocarmazine Byondis PM, Section 28
from the Pediatric Preclinical In Vivo Testing
(PIVOT) Consortium
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

The University of British

An IL1RAP ADC is efficacious in distinct April 30, 2025, 09:00 AM - 12:00
7055 / 25 X12-IL1RAP-PBD Columbia,University of IL1RAP
oncofusion-driven pediatric cancers PM, Section 28
Pittsburgh

The role of TROP2 in the MoA of Dato-DXd and

how it underpins the biologic rationale of the novel Datopotamab Daiichi Sankyo, Inc.; April 30, 2025, 09:00 AM - 12:00
7149 / 13 TROP-2
AI-guided biomarker TROP2 normalized deruxtecan AstraZeneca PLC PM, Section 32
membrane ratio

Targeting FAK exhibits therapeutic effects on AstraZeneca PLC;

Trastuzumab April 30, 2025, 09:00 AM - 12:00
7197 / 3 interstitial lung disease induced by trastuzumab Daiichi Sankyo, Inc.; HER-2
deruxtecan PM, Section 35
deruxtecan Alteogen, Inc.

GO Therapeutics; Cancer-specific Tn-

Status-agnostic therapy of breast cancer using April 30, 2025, 09:00 AM - 12:00
7209 / 15 LCB22A LigaChem Biosciences glycosylated
antibodies targeting O-glycosylated proteins PM, Section 35
Inc proteins
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

Trastuzumab Genentech, Inc.;

Novel humanized cell and murine models emtansine Hoffmann-La Roche AG
April 30, 2025, 09:00 AM - 12:00
7270 / 17 expressing tumor-associated antigens for ADC HER-2
AstraZeneca PLC; PM, Section 38
toxicity and IO combination evaluation Trastuzumab
Daiichi Sankyo, Inc.;
deruxtecan
Alteogen, Inc.

Phase I trial of trastuzumab deruxtecan in

Nanjing Leads Biolabs April 30, 2025, 09:00 AM - 12:00
7322 / 8 combination with neratinib in solid tumors with LBL-058 CD3, DLL3
Co Ltd PM, Section 40
HER2 alterations (NCI 10495)

Gilead Sciences; Everest

Sacituzumab
Medicines Ltd; TROP-2
govitecan
Anti-tumor activity of anti-body drug conjugates in Immunomedics Inc
April 30, 2025, 09:00 AM - 12:00
7328 / 14 patient-derived xenografts of metastatic breast
PM, Section 40
cancers patients AstraZeneca PLC;
Trastuzumab
Daiichi Sankyo, Inc.; HER-2
deruxtecan
Alteogen, Inc.
Abstract ID​ Title​ Drug Name​ Drug Developer Target​ Date, Time and Location​

B7-H7 is a novel ADC target for solid tumors and NextPoint

NextPoint Therapeutics HERV-H LTR- April 30, 2025, 09:00 AM - 12:00
7336 / 22 shows potent activity with multiple payload-linker Therapeutics B7-
Inc associating protein 2 PM, Section 40
technologies H7-ADC

Osimertinib treatment drives expression of

TROP2, and combination treatment with
datopotamab deruxtecan (Dato-DXd), a TROP2- Datopotamab Daiichi Sankyo, Inc.; April 30, 2025, 09:00 AM - 12:00
LB458 / 16 TROP-2
directed antibody-drug conjugate, enhances its deruxtecan AstraZeneca PLC PM, Section 53
efficacy in PDX models of EGFR mutant non
small-cell lung cancer
Abstract ID​ Title​ Date, Time and Location​

A dual-mechanism ADC targeting FAP-positive CAFs, to overcome chemo and April 27, 2025, 01:45 PM - 2:00 PM, Room S406
ND03
immunotherapy resistance in solid tumors (Vista Ballroom) - McCormick Place South (Level 4)

First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate

CT008 April 27, 2025, 03:00 PM - 3:10 PM
(ADC) for patients with advanced solid tumors

Safety profile assessment for IND-enabling studies: Bispecific antibodies and

LB009 / 9 April 27, 2025, 02:00 PM - 5:00 PM, Section 50
antibody-drug conjugates (ADCs)

Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-

CT039 / 18 April 28, 2025, 09:00 AM - 12:00 PM, Section 49
101)

Preliminary activity and safety of OBT076 in patients with CD205 positive solid
CT043 / 22 April 28, 2025, 09:00 AM - 12:00 PM, Section 49
tumors: Results from the phase 1b part C sequential expansion cohort
Abstract ID​ Title​ Date, Time and Location​

Overall safety of HS-20093, a B7-H3-directed antibody-drug conjugate in Chinese

CT179 / 19 April 29,2025, 09:00 AM - 12:00 PM, Section 49
patients with advanced solid tumors

A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3

CT195 / 12 protein targeted antibody-drug conjugate, in combination with standard of care in April 29,2025, 09:00 AM - 12:00 PM, Section 50
patients with advanced solid tumors

Resistance to trastuzumab deruxtecan (T-DXd) in breast cancer via loss of HER2

LB280 / 3 April 29,2025, 09:00 AM - 12:00 PM, Section 52
expression and binding

The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and re-
CT220 / 12 programmes CD33+ myeloid-derived suppressor cells in patients with metastatic April 29,2025, 02:00 PM - 5:00 PM, Section 50
cancer
Abstract ID​ Title​

495 Impact of lineage plasticity on regulating target expression for antibody-drug conjugate therapy in urothelial bladder cancer

6392 Next-generation ADCs: precise delivery of exatecan to tumor nuclei by targeting the tumor microenvironment with an anti-DNA cell-penetrating antibody

High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional
1230 / 14
characterization, screening and candidate selection

1565 / 14 Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7

Dual action tumor immune agonist (DATIA) ADCs activating STING pathway and subsequently inducing cytotoxicity of tumor cells exhibits potent and
1569 / 18
lasting in vivo tumor growth inhibition in multiple preclinical tumor antigen positive cancer models

1570 / 19 PermaLink®, a stable and scalable bioconjugation platform as an alternative to maleimide-based conjugation
Abstract ID​ Title​

Enhancing ADC efficacy through Fc-binding peptide engineered with ECM binding moiety: A versatile platform targeting various tumors and other
1790 / 9
malignancies

1793 / 12 Pre-targeting with in vivo click chemistry enables preferential drug exposure in tumors versus normal tissues

Pharmacological evaluation of bioconjugated trastuzumab using the AbYlink TM regio-selective conjugation technology in gastric cancer expressing
1825 / 11
HER2+

Prostate cancer lineage states detected by circulating tumor cell RNA sequencing are prognostic biomarkers for overall survival and resistance to
1974 / 9
androgen receptor pathway inhibitors and177Lutetium-PSMA-617

Leveraging spatial transcriptomics and proteomics to assess the Immune response and DNA damage in high grade serous ovarian cancer (HGSOC)
2099 / 2
treated with neoadjuvant chemotherapy

2150 / 4 Pre-targeted radioimmunotherapy using self-assembling dis-assembling (SADA) bispecific antibodies for the treatment of appendiceal carcinoma
Abstract ID​ Title​

2690 / 7 Expression profiles of antibody drug conjugate (ADC) targets in breast and lung cancer subtypes and in new HER2 subgroups with their PD-L1 status

2691 / 8 Configurable multiplex immunofluorescence panels for emerging ADC targets

2884 / 23 Development of antibody drug conjugates targeting MUC16 in ovarian cancer subtypes

2887 / 26 Next generation antibody drug conjugates targeting HER2 and TROP2: Multi-Payload Conjugates TM targeting orthogonal mechanisms of cell killing

2916 / 23 DNA polymerase theta inhibitor, ART6043, potentiates the efficacy of 177Lu- and 225Ac-based radioligand therapies in vitro and in vivo

2963 / 15 Loss of flotillin-2 enhances HER2 internalization and TDM1 efficacy in HER2 amplified cancer cells
Abstract ID​ Title​

3307 / 10 Utilizing endocytosis as a predictive biomarker for ADCs

334 / 1 proPBD-ADCs: optimization of therapeutic potential of ADCs based on capped PBD payload with attenuated potency

337 / 4 Highly potent, bispecific ADCs by application of clinical stage GlycoConnect® technology to bYlok® antibodies

The immunomodulatory effects of daratumumab-based therapy on functional high-risk relapse/refractory multiple myeloma (fHRMM) patients enrolled in
3402 / 22
the MyDRUG trial

3449 / 12 The role of N-terminal cleavage of Trop2 in tumor progression and therapeutic resistance in triple negative breast cancer
Abstract ID​ Title​

4425 / 28 Quantum-inspired computing analysis of spatial omics uncovers immune pathways relevant to T-DXd resistance in metastatic breast cancer

4692 / 19 Multimodal cancer therapy consisting of antibody-drug conjugates and radiotherapy in cancer treatment

4777 / 13 GDF-15 neutralization enhances the therapeutic activity of antibody-drug conjugates

50 / 29 Development of paired enfortumab vedotin-resistant urothelial cancer models using organoid and PDX

5195 / 10 Development of paired PDX-PDXO preclinical models for HER2-targeting ADC efficacy evaluation
Abstract ID​ Title​

5482 / 10 In vitro assays for prediction of ADC hematological toxicities: contribution of antibody, linker, and payload

5486 / 14 Bioluminescent assays for antibody-drug conjugate development: internalization and Fc-mediated functions

5500 / 28 A customizable, end-to-end platform for the screening and characterization of ADCs

5667 / 12 Epidemiology of tissue factor expression in soft tissue sarcoma

ThiOBI® platform, a novel hydrophilic linker for irreversible cysteine-selective biomolecular conjugation, demonstrated potent and durable antitumor
5675 / 20
activities in various animal models
Abstract ID​ Title​

5910 / 2 Characterizing spatial expression patterns and prevalence of folate receptor alpha in relation to other existing and emerging ovarian cancer biomarkers

5948 / 8 Sequencing of antibody drug conjugates (ADCs) in metastatic breast cancer: A real-world analysis

5950 / 10 Assessment of response and overall survival (OS) for various systemic therapies in ERBB2-altered advanced urothelial carcinoma (aUC)

5954 / 14 Real-world (RW) second-line (2L) treatment (tx) patterns and clinical outcomes in patients (pts) with HER2-overexpressing biliary tract cancer (BTC)

5980 / 7 Leveraging large-scale PDO-based assays to optimize antibody-drug conjugate efficacy in digestive cancer

5993 / 20 Identification of predictive biomarkers of response to ADCs by HTS of highly molecularly characterized panels of patient-derived organoids (PDOs)
Abstract ID​ Title​

6737 / 3 RAS inhibitors as payloads of ADCs to treat RAS-mutant tumors

Dual targeting of amyloid precursor protein with α-secretase inhibitor and antibody-drug conjugate synergistically reduces tumor progression in colorectal
6740 / 6
cancer

Comparison of activities and identification of predictive genomic biomarkers of response to trastuzumab and the trastuzumab deruxtecan ADC using the
6748 / 14
OncoPanel ® platform

6753 / 19 Exploring new approaches to widening of the therapeutic index of ADCs with dual-payload design and combination with a novel HMA

6754 / 20 A payload screening and ADC evaluation platform for STING agonist antibody drug conjugates
Abstract ID​ Title​

7026 / 26 Nanobody-PROTACs: Method development towards using single-domain antibodies to target undruggable proteins for degradation

7332 / 18 Investigating genes and pathways determining sensitivity or resistance to anti-L1cam ADCs in lymphomas

7463 / 8 Preclinical characterization of XB371, a novel anti-tissue factor antibody-drug conjugate

Summary
This Pre-Conference Planner has summarized 298 ADC-relevant abstracts, including Beacon links, to be presented at the AACR
Annual Meeting 2025.

Coming Up
The AACR Post-Conference Report is scheduled for publication in May 2025.

In the meantime, stay on top of the latest updates by signing up to our weekly newsletters here.
Copyright: Hanson Wade 2025
This planner has been created through considerable effort by Hanson Wade’s
Beacon ADC research team. The terms of subscription restrict usage of this work to
those who are named subscribers to the service. Unauthorized copying and/or
distribution of this document constitutes copyright infringement. If you are in doubt
about whether you are entitled to receive a copy of this planner, check with your
account holder or with Hanson Wade ([email protected])